Cargando…

A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina

The Hepatitis E virus (HEV) is an emergent virus that causes acute hepatitis in immunocompetent hosts and chronic hepatitis in immunocompromised hosts. In Latin America, the main circulating genotype HEV-3 is usually of zoonotic origin. Diagnosis and seroprevalence studies mainly rely on the detecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Arce, Lorena Paola, Müller, Melisa Florencia, Martinez, Alfredo, Baiker, Armin, Marranzino, Gabriela, Agote, Felicitas, Vizoso-Pinto, Maria Guadalupe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838658/
https://www.ncbi.nlm.nih.gov/pubmed/31736916
http://dx.doi.org/10.3389/fmicb.2019.02481
_version_ 1783467261879648256
author Arce, Lorena Paola
Müller, Melisa Florencia
Martinez, Alfredo
Baiker, Armin
Marranzino, Gabriela
Agote, Felicitas
Vizoso-Pinto, Maria Guadalupe
author_facet Arce, Lorena Paola
Müller, Melisa Florencia
Martinez, Alfredo
Baiker, Armin
Marranzino, Gabriela
Agote, Felicitas
Vizoso-Pinto, Maria Guadalupe
author_sort Arce, Lorena Paola
collection PubMed
description The Hepatitis E virus (HEV) is an emergent virus that causes acute hepatitis in immunocompetent hosts and chronic hepatitis in immunocompromised hosts. In Latin America, the main circulating genotype HEV-3 is usually of zoonotic origin. Diagnosis and seroprevalence studies mainly rely on the detection of specific antibodies. There are scarce data on the seroprevalence of HEV infection in Latin America mainly due to the lack of awareness of HEV circulation. Furthermore, in some countries, like Argentina, HEV testing is not included in routine assays. In order to provide tools to deepen the knowledge on HEV epidemiology in South America, we designed a new in-house ELISA based on the native recombinant protein ORF2 aa112–608 and demonstrated its potential for detecting anti-HEV immunoglobulin G (IgG) in human serum samples. The following conditions were determined: an optimal antigen concentration of 0.25 μg/ml, a serum dilution of 1:80, gelatin as a blocking agent, and a secondary antibody dilution of 1:2000. A relative sensitivity of 93.33% (95% CI: 77.9–99.2%) and a relative specificity of 99.4% (95% CI: 96.7–100%) were determined using a panel of previously characterized sera and a gold standard (HEV IgG ELISA, DIA.PRO, Italy). Further, we obtained a very good agreement (κ index = 0.94, 95% CI: 0.87–1.00) with the gold standard. We screened 813 blood donor samples with this newly developed ELISA and found a seroprevalence of 9.23% (95% confidence interval, 7.33–11.43%). We show for the first time evidence of past HEV infection in Tucuman, the most populated city in northern Argentina. We expect that this study will raise the interest of health decision makers who should intercede to include indirect testing of HEV in regular diagnostic protocols. In conclusion, the in-house ELISA developed in this work shows a very good agreement with an already licensed commercial HEV IgG ELISA (DIA.PRO, ITALY), which can be used as an epidemiologic tool for HEV surveillance.
format Online
Article
Text
id pubmed-6838658
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68386582019-11-15 A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina Arce, Lorena Paola Müller, Melisa Florencia Martinez, Alfredo Baiker, Armin Marranzino, Gabriela Agote, Felicitas Vizoso-Pinto, Maria Guadalupe Front Microbiol Microbiology The Hepatitis E virus (HEV) is an emergent virus that causes acute hepatitis in immunocompetent hosts and chronic hepatitis in immunocompromised hosts. In Latin America, the main circulating genotype HEV-3 is usually of zoonotic origin. Diagnosis and seroprevalence studies mainly rely on the detection of specific antibodies. There are scarce data on the seroprevalence of HEV infection in Latin America mainly due to the lack of awareness of HEV circulation. Furthermore, in some countries, like Argentina, HEV testing is not included in routine assays. In order to provide tools to deepen the knowledge on HEV epidemiology in South America, we designed a new in-house ELISA based on the native recombinant protein ORF2 aa112–608 and demonstrated its potential for detecting anti-HEV immunoglobulin G (IgG) in human serum samples. The following conditions were determined: an optimal antigen concentration of 0.25 μg/ml, a serum dilution of 1:80, gelatin as a blocking agent, and a secondary antibody dilution of 1:2000. A relative sensitivity of 93.33% (95% CI: 77.9–99.2%) and a relative specificity of 99.4% (95% CI: 96.7–100%) were determined using a panel of previously characterized sera and a gold standard (HEV IgG ELISA, DIA.PRO, Italy). Further, we obtained a very good agreement (κ index = 0.94, 95% CI: 0.87–1.00) with the gold standard. We screened 813 blood donor samples with this newly developed ELISA and found a seroprevalence of 9.23% (95% confidence interval, 7.33–11.43%). We show for the first time evidence of past HEV infection in Tucuman, the most populated city in northern Argentina. We expect that this study will raise the interest of health decision makers who should intercede to include indirect testing of HEV in regular diagnostic protocols. In conclusion, the in-house ELISA developed in this work shows a very good agreement with an already licensed commercial HEV IgG ELISA (DIA.PRO, ITALY), which can be used as an epidemiologic tool for HEV surveillance. Frontiers Media S.A. 2019-11-01 /pmc/articles/PMC6838658/ /pubmed/31736916 http://dx.doi.org/10.3389/fmicb.2019.02481 Text en Copyright © 2019 Arce, Müller, Martinez, Baiker, Marranzino, Agote and Vizoso-Pinto. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Arce, Lorena Paola
Müller, Melisa Florencia
Martinez, Alfredo
Baiker, Armin
Marranzino, Gabriela
Agote, Felicitas
Vizoso-Pinto, Maria Guadalupe
A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina
title A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina
title_full A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina
title_fullStr A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina
title_full_unstemmed A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina
title_short A Novel In-House Enzyme-Linked Immunosorbent Assay for Genotype 3 Hepatitis E Virus Reveals High Seroprevalence in Blood Donors in Northern Argentina
title_sort novel in-house enzyme-linked immunosorbent assay for genotype 3 hepatitis e virus reveals high seroprevalence in blood donors in northern argentina
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838658/
https://www.ncbi.nlm.nih.gov/pubmed/31736916
http://dx.doi.org/10.3389/fmicb.2019.02481
work_keys_str_mv AT arcelorenapaola anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT mullermelisaflorencia anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT martinezalfredo anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT baikerarmin anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT marranzinogabriela anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT agotefelicitas anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT vizosopintomariaguadalupe anovelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT arcelorenapaola novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT mullermelisaflorencia novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT martinezalfredo novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT baikerarmin novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT marranzinogabriela novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT agotefelicitas novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina
AT vizosopintomariaguadalupe novelinhouseenzymelinkedimmunosorbentassayforgenotype3hepatitisevirusrevealshighseroprevalenceinblooddonorsinnorthernargentina